Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Genes included in the breast cancer panel sequenced by UDT-Seq

From: Evaluation of ultra-deep targeted sequencing for personalized breast cancer care

Gene Rationale for inclusiona Molecular eligibility for clinical trial US FDA-approved pathway inhibitor Pathway inhibitor in clinical testing
PIK3CA S, Y   Y
PTEN S, G Y   Y
BRAF S,   Y Y
KRAS S,    Y
EGFR S,   Y Y
ALK S, Y Y Y
ERBB2 S, Y Y Y
JAK2 S,   Y  
PDGFRB S,   Y  
RET S, G   Y  
JAK1 S,   Y  
RARA S,   Y  
TP53 S, G    
CDH1 S,    
GATA3 S,    
CTNNA1 S,    
RB1 S, G    
CDKN2A S,    Y
AKT1 S,   Y Y
APC S, G    
PIK3R1 S,    
BRCA1 S, G    Y
ERBB3 S,    
JAK3 S,   Y  
NOTCH1 S,    Y
MET S, G   Y Y
FGFR2 S, Y   Y
ABL2 S,    
BRCA2 S, G    Y
CTNNB1 S,    
ERBB4 S,    Y
FGFR1 S, Y   Y
FGFR1OP S,    
PALB2 S, G    
TOP1 S,   Y  
DPD P (capecitabine/5-fluorouracil)    
TPMT P (6-mercaptopurine thioguanine)    
CYP2D6 P (tamoxifen (+/-))    
CYP2C9 P (warfarin)    
VKORC1 P (warfarin)    
CFTR R (cystic fibrosis)    
MLH1 G    
MSH2 G    
MSH6 G    
PMS2 G    
CHK2 G    
ATM G    
  1. FDA, Food and Drug Administration; UDT-Seq, ultra-deep targeted sequencing. aS somatic mutations; G, germline cancer risk; P, pharmacogenetic risk; R, reproductive significance.